ADR Biomedical Holdings (TSE:3750) Research & Development: 円153.28 Mil (TTM As of Mar. 2026)


TSE:3750 ADR Biomedical Holdings Inc TSE:3750
30 GF Score
Price 円805.00
GF Value 円40.42
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is ADR Biomedical Holdings Research & Development?

ADR Biomedical Holdings TSE:3750 -1.23% 30 Research & Development is 円153.28 Mil as of Mar. 2026. GuruFocus rates TSE:3750 with a GF Score™ of 30/100 and a GF Value™ of 円40.42 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. ADR Biomedical Holdings's Research & Development for the six months ended in Mar. 2026 was 円64.06 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was 円153.28 Mil.

ADR Biomedical Holdings  (TSE:3750) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

ADR Biomedical Holdings Research & Development Related Terms

ADR Biomedical Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for ADR Biomedical Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADR Biomedical Holdings Research & Development Chart

ADR Biomedical Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 145.24 351.35 202.95 153.28

ADR Biomedical Holdings Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 174.58 90.79 112.15 89.22 64.06
TSE:3750
30GF Score
ADR Biomedical Holdings Inc TSE:3750
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ADR Biomedical Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円153.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of 円153.28 Mil mean?
ADR Biomedical Holdings (TSE:3750) has a Research & Development of 円153.28 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on ADR Biomedical Holdings and its competitors.
Is ADR Biomedical Holdings' Research & Development too high?
ADR Biomedical Holdings' current Research & Development is 円153.28 Mil. Overall, ADR Biomedical Holdings has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ADR Biomedical Holdings' Research & Development compare to VRTX and REGN?
ADR Biomedical Holdings' Research & Development of 円153.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on ADR Biomedical Holdings and its competitors. ADR Biomedical Holdings's current Research & Development is 円153.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADR Biomedical Holdings stock overvalued right now?
Based on GuruFocus' analysis, ADR Biomedical Holdings (TSE:3750) is currently considered Significantly Overvalued. The stock's GF Value™ is 円40.42, compared to a current price of 円805.00 — trading 1891.6% above its estimated fair value. The current Research & Development is 円153.28 Mil. ADR Biomedical Holdings' overall GF Score™ is 30/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For ADR Biomedical Holdings (TSE:3750), the current Research & Development is 円153.28 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?

Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued. The current stock price of 円805.00 is trading 1891.6% above its estimated GF Value™ of 円40.42. GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.

Key valuation signals for TSE:3750:

  • Research & Development: 円153.28 Mil
  • GF Value™: 円40.42 vs. price of 円805.00 (1891.6% above fair value)
  • GF Score™: 30/100 with 9 warning signs

No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ADR Biomedical Holdings Business Description

Address 1-1-1 Otemachi, Otemachi Park Building, Chiyoda-ku, Tokyo, JPN, 100-0004
ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.
30GF Score

Get the complete analysis for TSE:3750

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円805.00
Price
円40.42
GF Value